IL5RA and chronic obstructive pulmonary disease: The ABRA trial tested benralizumab (anti-IL5Rα) during active eosinophilic exacerbations of asthma/COPD and evidenced a reduced failure rate (against prednisolone) and reduced hospital readmissions [67].